CJC-1295 No-DAC + Ipamorelin blend
Pre-mixed CJC-1295 No-DAC + Ipamorelin. Pre-mix vs separate-vial tracking implications.
- Half-life
- Not established
- Out of system
- —
- Route
- Subcutaneous
- Level
- Intermediate
What CJC-1295 No-DAC + Ipamorelin blend is used for
- Pre-mixed CJC-1295 No-DAC + Ipamorelin — one injection
- Convenient for daily GH-axis protocols
How it's typically used
Research range: per-vial label, dosed 1–3× daily pre-meal/pre-bed.
What to watch for
- Fixed ratio removes per-compound dose control
- Same GH-side effects (water, glucose, joints)
- Avoid with cancer, diabetes, or pituitary issues
About Performance & GH
- What they are
- Growth-hormone secretagogues and related performance compounds. Rather than supplying GH, they push your pituitary to release more of its own in a pulse.
- How they're run
- Subcutaneous injection, most often at night on an empty stomach so the pulse lands with natural sleep-driven GH release.
- What to watch
- Water retention, tingling hands, and hunger swings are the common early signs. Raising GH raises IGF-1 — worth tracking on bloodwork, and a reason to avoid these with any cancer history.
Full guide
CJC-1295 No-DAC + Ipamorelin Pre-Blend: Practical Tracking
What to know about using a pre-mixed CJC-1295/ipamorelin blend versus separate vials, and how it affects your tracking.
Other performance & gh
Peptid AI is an educational and self-tracking tool — not a medical service, and not a vendor. Nothing here is medical advice, a prescription, or an endorsement. Doses reflect what is commonly reported in research literature; they are not recommendations. Many compounds listed are experimental, not approved for human use, and/or controlled substances that are illegal to possess without a prescription in many countries. Always consult a qualified physician before starting, changing, or stopping any protocol.